You are here: Industry Insights > Aveo Oncology

News List

AVEO Oncology announces FDA acceptance for filing of an NDA for Tivozanib as treatment of relapsed o pharmaceutical-business-review
June 04, 2020
AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib ...
AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis pharmaceutical-business-review
April 01, 2020
AVEO Oncology and Biodesix announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab.
Kyowa Kirin buys back Tivozanib rights from AVEO oncology biospectrumasia
August 04, 2019
Kyowa Kirin will reobtain the non-oncology rights of tivozanib in AVEO territories excluding the rights which are currently sublicensed to EUSA Pharma
AVEO Oncology warns of "regulatory action" by EMA if overall survival results for Fotivda come up short firstwordpharma
April 04, 2019
AVEO Oncology disclosed in a filing with the US Securities and Exchange Commission that the European Medicines ……
AVEO Oncology Announces Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma americanpharmaceuticalreview
June 22, 2017
AVEO Oncology announced the company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target of 322